Immutrin raises $87M to advance drug for progressive heart disease
BioPharma Dive
The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, ATTR-CM, that has become a battleground for companies like Pfizer, Alnylam and BridgeBio.
pharminent
March 24, 2026 (Last updated: March 25, 2026)
BioPharma Dive
The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, ATTR-CM, that has become a battleground for companies like Pfizer, Alnylam and BridgeBio.
